MeiraGTx Holdings plc - Ordinary Shares (MGTX) News
Filter MGTX News Items
MGTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MGTX News Highlights
- For MGTX, its 30 day story count is now at 4.
- Over the past 11 days, the trend for MGTX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DEC and EU are the most mentioned tickers in articles about MGTX.
Latest MGTX News From Around the Web
Below are the latest news stories about MEIRAGTX HOLDINGS PLC that investors may wish to consider to help them evaluate MGTX as an investment opportunity.
Wall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 221.8% in MeiraGTx Holdings PLC (MGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! |
J&J bets bigger on MeiraGTx’s eye gene therapyAhead of a Phase 3 readout that could come next year, the pharma is paying $130 million in upfront and near-term cash for rights to the retinitis pigmentosa treatment that it didn’t already own. |
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million- MeiraGTx enters into an Asset Purchase Agreement related to botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) for a total of up to $415 million - MeiraGTx to receive $130 million in upfront and near-term milestone payments as part of the agreement - MeiraGTx to receive up to an additional $285 million upon first commercial sales of bota-vec in U.S. and EU and manufacturing technology transfer LONDON and NEW YORK, Dec. 21, 2023 (G |
The past three years for MeiraGTx Holdings (NASDAQ:MGTX) investors has not been profitableThe truth is that if you invest for long enough, you're going to end up with some losing stocks. But the last three... |
MeiraGTx to Participate in Upcoming Investor ConferencesLONDON and NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences: 6th Annual Evercore ISI HealthCONx Conference Corporate presentation: Tuesday, November 28, 2023, at 10:25 a.m. ET Piper Sandler 35th Annual Healthcare Conference Corporate presentation: Thursday, Novembe |
MeiraGTx Holdings PLC Reports Q3 2023 Financial Results and Operational ProgressStrategic Investment from Sanofi and Advancements in Gene Therapy Programs Highlighted |
MeiraGTx Announces Third Quarter 2023 Financial and Operational Results- Received strategic investment from Sanofi purchasing $30 million of ordinary shares of the Company at a price of $7.50 per share in October 2023 - Announced a right of first negotiation (ROFN) with Sanofi for the use of MeiraGTx’s Riboswitch gene regulation technology for certain Central Nervous System (CNS) and Immunology and Inflammation (I&I) targets, including IL-4 and IL-13, as well as for GLP-1 and other gut peptides for metabolic disease, and for MeiraGTx’s Phase 2 Xerostomia program - |
BestGrowthStocks.Com: MeiraGTx Holdings plc Actively Pursuing Strategic Partnerships and Asset Interest, Potential TransactionsBest Growth Stocks, a leading independent research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a co... |
Sanofi invests in MeiraGTx and its gene-regulating technologyIn addition to Sanofi’s investment, the biotech signaled it’s weighing deals with “multiple” other companies that have expressed interest in its work. |